Business
CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress
Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure
About this update from Caredx, Inc.
[{"type":"text","content":"Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure\nSOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation in the 2021 American Transplant Congress (ATC), including two symposia and the presentation of 40 scientific abstracts. “We look forward to sharing groundbreaking findings from ADMIRAL and KOAR, both multi-center, prospective studies as we continue to drive innovation in transplantation,” said Reg Seeto, President & CEO of CareDx. “These are the first long-term studies on donor-derived cell-free DNA. They are part of 40 scientific abstracts from more than 30 authors, representing 25 centers, related to CareDx solutions accepted by ATC.” The first symposium, scheduled for Sunday, June 6, 2021 from 1:30-2:30 p.m. EDT will cover AlloSure utility in heart, lung, and liver transplant recipients. Featured speakers: Mario Deng, MD, FACC, FESC, UCLA HealthManreet Kanwar, MD, Allegheny General HospitalSam Weigt, MD, UCLA HealthDeborah Jo Levine, MD, UT San AntonioSander Florman, MD, Mount Sinai The second symposium, scheduled for Monday, June 7, 2021 from 1:30-2:30 p.m. EDT will highlight findings from the ADMIRAL study, the largest multi-center report looking at real-world prospective utility of AlloSure. Speakers will also present one-year data from the first 1,000 patients enrolled in the KOAR study, a landmark registry that evaluates AlloSure utility in discriminating rejection from no rejection, impact on the reduction in number of biopsies, and ability to prognosticate graft survival rates in kidney transplant recipients. Featured speakers: Gaurav Gupta, MD, VCU HealthLihong Bu, MD, PhD, University of Minnesota Medical CenterTarek Alhamad, MD, MS, FACP, FASN, Washington University School of Medicine in St. LouisJonathan S. Bromberg, MD, PhD, University of Maryland School of MedicineStanley C. Jordan, MD, Cedars-Sinai Medical Center “ATC is one of the premier events for clinicians and scientists in transplantation to come together and share the best the fi...